Form 4: Revance Therapeutics CMO Hollander Disposes of Shares Following Merger Completion
SEC Form 4 Filing
Following the completion of a merger with Crown Laboratories, Revance Therapeutics' CMO David Hollander reports the disposal of common stock and cancellation of restricted stock units.
Summary
- David Hollander, CMO & Global Therapeutics Lead at Revance Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On February 4, 2025, Hollander disposed of 9,733 shares of common stock at $3.65 per share.
- This disposal was pursuant to the merger agreement with Crown Laboratories, where Revance Therapeutics was acquired.
- On February 6, 2025, Hollander's 95,212 restricted stock units (RSUs) were canceled and converted into cash based on the merger agreement's terms.
- The merger involved a cash tender offer for all outstanding shares of Revance Therapeutics at $3.65 per share.
- The reporting person no longer holds any shares after the transaction.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it primarily reports the execution of a previously announced merger agreement. There are no indications of positive or negative surprises.
Future Outlook
The document does not contain any forward-looking statements regarding the company's future outlook as it pertains to Revance Therapeutics, as the company has been acquired.
Industry Context
This announcement reflects the completion of a merger transaction, a common occurrence in the biopharmaceutical industry as companies seek to consolidate resources, expand product portfolios, or gain access to new technologies. Mergers and acquisitions can lead to increased efficiency and market share but also pose integration challenges.
Stakeholder Impact
- Shareholders received $3.65 per share as part of the merger agreement.
- Employees may experience changes as a result of the merger, such as integration into Crown Laboratories.
Key Dates
| Date | Description |
|---|---|
| December 7, 2024 | Date of the Amended and Restated Agreement and Plan of Merger between Revance Therapeutics and Crown Laboratories. |
| February 4, 2025 | Date of disposal of common stock. |
| February 6, 2025 | Date of RSU cancellation and conversion to cash. |
Keywords
Revance Therapeutics, Crown Laboratories, Merger, Form 4, Beneficial Ownership, Hollander, Shares, RSU, Disposition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.